AbbVie's immunology newbies Skyrizi and Rinvoq pick up the slack from declining Humira, but safety questions dog execs

When AbbVie won FDA approval for its next-generation immunology drugs Skyrizi and Rinvoq in 2019, the company had high hopes that the drugs could fill what threatened to be a gaping hole in the top line from the impending patent losses on the $20-billion-a-year Humira. Wall Street skeptics weren’t so sure.